Highlights Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
72.5 ^USD	-1.60%		-3.07%	-8.91%

08/05	Mizuho Securities Adjusts Price Target on Axsome Therapeutics to $106 From $109, Maintains Buy Rating	MT
07/05	Baird Adjusts Price Target on Axsome Therapeutics to $112 From $108, Maintains Outperform Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Axsome Therapeutics Q1 Loss Widens, Revenue Declines -- Shares Advance Pre-Bell	06/05	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q1 Revenue $75M, vs. Street Est of $72.9M	06/05	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05	CI
North American Morning Briefing : More Earnings -2-	30/04	DJ
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	01/04	CI
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment	25/03	MT
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	25/03	CI
Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial	25/03	RE
Axsome Therapeutics, Inc. Announces AXS-12 Achieves Primary Endpoint in the SYMPHony Phase 3 Trial in Narcolepsy	25/03	CI
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	19/03	CI
Axsome Therapeutics Q4 Net Loss Widens, Revenue Rises; Shares Drop	20/02	MT
Axsome Therapeutics Q4 Net Loss Widens, Revenue Rises	20/02	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Reports Q4 Revenue $71.5M, vs. Street Est of $69M	20/02	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/02	CI
Axsome Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/02	CI
North American Morning Briefing : Earnings Back in -2-	20/02	DJ
Axsome Therapeutics Q3 Net Loss Widens, Revenue Rises	06/11	MT
Earnings Flash (AXSM) AXSOME THERAPEUTICS Posts Q3 Revenue $57.8M, vs. Street Est of $54.9M	06/11	MT
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11	CI
Axsome Therapeutics, Inc. Presents Results of the Accord Trial of AXS-05 in Alzheimer's Disease Agitation at the Clinical Trials on Alzheimer's Disease Agitation at its Clinical Trials on Alzheimer's Disease 2023 Conference	24/23/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Highlights

Filters